LCG
TVTX icon

Lisanti Capital Growth’s Travere Therapeutics TVTX Stock Holding History

Lisanti Capital Growth’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.76M Buy
119,005
+70,820
+147% +$3.14M 1.49% 17
2026
Q1 		$1.43M Sell
48,185
-90,297
-65% -$2.7M 0.36% 90
2025
Q4 		$5.29M Buy
138,482
+8,970
+7% +$292K 1.25% 28
2025
Q3 		$3.1M Buy
+129,512
New +$2.43M 0.76% 64

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lisanti Capital Growth's TVTX Position: Q2 2026 in Review

Lisanti Capital Growth increased its Travere Therapeutics (TVTX) stake by 147% in Q2 2026, buying an estimated $3.14M and bringing the position to 119,005 shares worth $6.76M. The position accounts for 1.49% of the portfolio, ranked #17.

Lisanti Capital Growth first reported a position in TVTX in Q3 2025 and has held it in 4 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Lisanti Capital Growth held 119,005 shares of Travere Therapeutics worth $6.76M as of Q2 2026.
  • Lisanti Capital Growth bought 70,820 Travere Therapeutics shares in Q2 2026, an estimated $3.14M.
  • Travere Therapeutics made up 1.49% of Lisanti Capital Growth's portfolio in Q2 2026, its #17 holding.
  • Lisanti Capital Growth first reported a position in Travere Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.